Share on LinkedInShare on LinkedIn

ARTICLE · 17 OCTOBER 2024

Safeguarding Clinical Trial Data In The Age Of Artificial Intelligence & Data Breaches

The data derived from clinical trials is one of the most important assets in new drug discovery, especially for companies seeking investment.

United StatesTechnology

The data derived from clinical trials is one of the most important assets in new drug discovery, especially for companies seeking investment. AI can be used in many ways in the drug discovery process, including identifying target compounds to treat specific diseases and drug product development. AI also has vast potential to enhance the capacity to analyze clinical trial data for scientific and patient outcome purposes. It can speed data analysis, help sponsors identify and recruit participants, and add efficiencies that save valuable time and capital. Yet, reliance on advanced, data-driven technologies also carries risks, requiring trial sponsors to responsibly manage and oversee how they use the data generated through the trial.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from